Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Biopsies from metastatic Clear Cell Renal Carcinoma before or after treatment with nivolumab


ABSTRACT: Tumor core needle biopsies from kidney or metastatic sites obtained at trial enrollment i.e. Screen and/or at Cycle 2 Day 8 (i.e.Week 4) from metastatic clear cell RCC patients treated with 0.2mpk, 3mpk or 10mpk (as 2nd or further line of therapy; Arms A,B,C) or 10mpk (as first line therapy; Arm D) of nivolumab (BMS-936558,MDX-1106) on Bristol-Myers Squibb clinical trial protocol CA209-009.

INSTRUMENT(S): Gene Titan

ORGANISM(S): Homo sapiens

SUBMITTER: Petra Ross-Macdonald 

PROVIDER: E-MTAB-3218 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


<h4>Purpose</h4>Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with metastatic renal cell carcinoma (mRCC). We investigated immunomodulatory activity of nivolumab in a hypothesis-generating prospective mRCC trial.<h4>Experimental design</h4>Nivolumab was administered intravenously every 3 weeks at 0.3, 2, or 10 mg/kg to previously treated patients and 10 mg/kg to treatment-naïve patients with mRCC  ...[more]

Similar Datasets

2016-05-15 | E-MTAB-3219 | biostudies-arrayexpress
2022-01-01 | E-MTAB-4030 | biostudies-arrayexpress
2018-02-07 | GSE110174 | GEO
2018-02-06 | GSE110161 | GEO
2018-02-06 | GSE110160 | GEO
2017-02-09 | GSE86200 | GEO
2013-07-30 | E-GEOD-37138 | biostudies-arrayexpress
2020-12-31 | GSE162436 | GEO
2024-02-29 | GSE249860 | GEO
2024-01-29 | GSE253243 | GEO